Williams-Gray CH - Search Results

1

Validation of a 5-Year Prognostic Model for Parkinson's Disease.

Ribeiro J, Camacho M, Scott KM, Greenland JC, Evans JR, Breen DP, Wijeyekoon RS, Barker RA, Williams-Gray CH. Ribeiro J, et al. Among authors: williams gray ch. Mov Disord Clin Pract. 2024 Nov;11(11):1441-1444. doi: 10.1002/mdc3.14215. Epub 2024 Sep 29. Mov Disord Clin Pract. 2024. PMID: 39344276 Free PMC article.

2

Saccadic latency distributions in Parkinson's disease and the effects of L-dopa.

Michell AW, Xu Z, Fritz D, Lewis SJ, Foltynie T, Williams-Gray CH, Robbins TW, Carpenter RH, Barker RA. Michell AW, et al. Exp Brain Res. 2006 Sep;174(1):7-18. doi: 10.1007/s00221-006-0412-z. Epub 2006 Mar 17. Exp Brain Res. 2006. PMID: 16544135 Free PMC article.

3

No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease.

Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA. Williams-Gray CH, et al. Mov Disord. 2006 May;21(5):731-2. doi: 10.1002/mds.20863. Mov Disord. 2006. PMID: 16552758 No abstract available.

4

Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.

Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA. Williams-Gray CH, et al. J Neurol Neurosurg Psychiatry. 2006 May;77(5):665-7. doi: 10.1136/jnnp.2005.085019. J Neurol Neurosurg Psychiatry. 2006. PMID: 16614029 Free PMC article.

5

Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.

Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA. Williams-Gray CH, et al. CNS Drugs. 2006;20(6):477-505. doi: 10.2165/00023210-200620060-00004. CNS Drugs. 2006. PMID: 16734499 Review.

6

Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia.

Williams-Gray CH, Barker RA. Williams-Gray CH, et al. Nat Clin Pract Neurol. 2007 May;3(5):250-1. doi: 10.1038/ncpneuro0471. Epub 2007 Mar 20. Nat Clin Pract Neurol. 2007. PMID: 17375057 No abstract available.

7

Investigation of TGFB2 as a candidate gene in multiple sclerosis and Parkinson's disease.

Goris A, Williams-Gray CH, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Barker RA, Sawcer SJ. Goris A, et al. J Neurol. 2007 Jul;254(7):846-8. doi: 10.1007/s00415-006-0414-6. J Neurol. 2007. PMID: 17431704

8

Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease.

Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA. Williams-Gray CH, et al. J Neurosci. 2007 May 2;27(18):4832-8. doi: 10.1523/JNEUROSCI.0774-07.2007. J Neurosci. 2007. PMID: 17475791 Free PMC article.

9

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Williams-Gray CH, et al. Brain. 2007 Jul;130(Pt 7):1787-98. doi: 10.1093/brain/awm111. Epub 2007 May 29. Brain. 2007. PMID: 17535834 Review.

10

Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease.

Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, Sawcer SJ. Goris A, et al. Ann Neurol. 2007 Aug;62(2):145-53. doi: 10.1002/ana.21192. Ann Neurol. 2007. PMID: 17683088

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

156 results

Search Page

Filters